Deep Blue Medical Advances Inc., a biotechnology company based in Durham, North Carolina, raised $295,000, according to a Securities and Exchange Commission filing.

The corporation, which was formed in 2015, filed a Form D on Aug. 30. It did not disclose what it intends to do with the proceeds.

Deep Blue’s founder and chief medical officer Howard Levinson invented the company’s primary products, the T-line Mesh and Anchor Clips. These technologies are meant to replace sutures and prevent the re-opening of a wound after surgery.

Deep Blue’s technology is especially useful after hernia surgeries because it can redistribute stress put on a wound by lifting heavy things or coughing, preventing the wound from re-opening.

Levinson earned his medical degree from the University of Texas Medical Branch at Galveston in 1997 and focuses on wound healing and abdominal wall repair. He is an associate professor of surgery, pathology and dermatology at Duke University.

Levinson and Deep Blue Medical Advances worked with Duke University’s Office of Licensing and Ventures to secure intellectual property and raise non-dilutive grant funds. They are now working toward releasing their products for commercial distribution and claiming part of the approximately $1.1 billion spent in the hernia device market.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what is known as a Form D electronically with the SEC after they first sell their securities.

The form can be found here.